ReviewUrologie (Heidelberg, Germany)2025
[Human papillomavirus (HPV) vaccination for cancer prevention].
Review in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2005, the first approval study of a preventive quadrivalent human papillomavirus (HPV) vaccine in young women triggered vaccination strategies around the world.
objectiveWe aimed to investigate how successful these vaccination interventions have been in preventing cancer so far.
methodsTo this end, we reviewed the relevant literature of the past two decades regarding vaccination rates and the subsequent decline in HPV-associated diseases worldwide.
resultsFor various reasons, many countries that offer HPV vaccinations are still missing their goals for primary cancer prevention. In Germany, for example, vaccination rates are completely inadequate, and urologists are not even recognized as vaccinators.
conclusionCancer prevention through HPV vaccination is zur Hausen's scientific legacy to the world. However, each country must continuously analyze and combat its specific reasons for failing in HPV vaccination. New HPV vaccines will continue the global success story in the future.
Indexed as
Identifiers
40304730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.